Viragen hat angeblich auch ein Mittel gegen alle Viren... - 500 Beiträge pro Seite

[mibaxelf]

Aber die Bude steht kurz vor der Pleite !!!

[mibaxelf]

Nur ein letztes aufbäumen im KURS; AUFGRUND VON VÖLLIG HALTLOSEN SPEKULATIONEN !!!

[mibaxelf]

Wer die Dinger echt kauft hat echt nix gelernt ! Das ist das typische Muster bevor Chapter 11 angemeldet wird. Vorher noch ein paar News wie : Wir haben ein Mittel gegen SARS, damit der Kurs noch mal richtig anspringt um den letzten Dummen noch mit reinzureißen und dann Plopp ! Der letzte macht das Licht aus !

[steffen712000]

klaro und du hast es gelernt! deshalb treibst du dich selbstlos und weihrauch zerstäubend hier rum

so sinnlos in D zu motzen

[gholzbauer]

Wow! Ein Mittel gegen ALLE Viren.
Was ist es denn? Eine nukleare Bombe?

[ebihard1]

Just for Info



Viragen Signs Drug Distribution Agreement for Hong Kong

VIRAGEN LOGO
Viragen logo. (PRNewsFoto)[TK]
PLANTATION, FL USA 09/28/2002





PLANTATION, Fla., May 22 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) and Viragen International, Inc. (OTC Bulletin Board: VGNI) today
announced that the Companies have entered into an exclusive distribution
agreement with CJ Pharma, U.S. Pharmaceutical Division of CJ Corporation, and
the CJ Hong Kong Ltd. subsidiary, as exclusive distributors of natural
interferon in Hong Kong. Viragen`s human leukocyte-derived alpha interferon
is currently approved in Hong Kong as a second-line therapy for the treatment
of patients with Hairy Cell Leukemia (HCL) or Chronic Myelogenous Leukemia
(CML) who did not respond to recombinant (synthetic) interferon regimens.
CJ Corporation (formerly Cheil Jedang) was established as the first
manufacturing operation unit of the Samsung Group in 1953. Now a split-off of
Samsung Group, the CJ Group recorded over $6 billion in revenues last year,
conducting business with over 60 different countries through its thirty-two
offices around the world.
"We are very pleased to build upon our relationship with a proven leader
such as CJ Pharma," stated Viragen`s Executive Vice President, Mel Rothberg.
"We have been working very closely with CJ to commercialize our natural
interferon in previously assigned territories in Latin America. Now we are
expanding our work together to include the introduction of the drug into the
Hong Kong market."
CJ Pharma exclusively represents Viragen`s products in the following
territories: Brazil, Chile, Uruguay, Peru, Costa Rica, Honduras, Nicaragua,
Guatemala, Panama and Hong Kong. CJ Pharma is responsible for all costs
associated with the regulatory approval process, including clinical trials if
required, in each of the respective countries.
CJ Hong Kong`s General Manager, Mr. Jong Hwan Park, stated, "We are
excited to attain the rights to distribute such a potent anti-viral product
with Viragen`s multi-subtype human interferon. Our immediate priority is to
expand the indications for which the product is currently approved to include
a broad range of viral and malignant diseases and we are proceeding with the
regulatory registration process."
Dr. Andrew Gorman, Vice President, CJ Pharma (Princeton, NJ), stated, "We
believe that natural interferon represents a very attractive international
market opportunity for us and our commitment to Viragen now extends from South
America to Asia. Our foremost priority is to offer products that promote
better health for everyone and this immune-enhancing drug offers that kind of
promise in treating a variety of diseases."

Backgrounder:
The majority of alpha interferons that are marketed are single-subtype
recombinant interferons. Therapy resistance is not unusual with recombinant
interferons with a significant percentage of patients failing to respond to
standard therapy. In some instances, recombinant interferon is rejected by
the patient`s immune system, usually caused by the formation of neutralizing
antibodies which may lead to a loss of clinical efficacy. Also, many patients
cannot tolerate the adverse side-effects sometimes associated with recombinant
therapy. High doses of recombinant interferon may cause serious, even life-
threatening side effects.

The Natural Choice
Viragen believes that in many cases, especially when higher dosages are
required, its natural interferon appears to offer substantial advantages to
recombinant interferon regimens:
* Natural interferon is very similar to interferon secreted by the human
immune system during a normal virus infection, significantly lowering the risk
of the drug being rejected.
* Natural interferon contains the multiple subtype composition that is
characteristic of interferon produced by the human body. It is believed that
this may result in a broader spectrum of anti-viral activity with each subtype
perhaps showing a specific biological activity.
* Natural interferon does not appear to cause the formation of
neutralizing antibodies.
* Natural interferon is significantly less immunogenic than recombinant
interferon. It should be far better tolerated by patients with fewer side
effects and thus allow for higher doses to be administered to maximize the
benefits of the therapy.

About CJ Corporation:
CJ Corporation (formerly Cheil Jedang) was established as the first
manufacturing operation unit of the Samsung Group in 1953. The CJ Group
recorded over $6 billion in revenues last year, conducting business with over
60 different countries through its thirty-two offices around the world. CJ
Pharma is the pharmaceutical division in the U.S. and is the exclusive
distributor of Viragen`s natural interferon in South America and Hong Kong.

About Viragen, Inc.
Viragen is a biotechnology company specializing in the research,
development and commercialization of natural and recombinant protein-based
drugs designed to treat a broad range of viral and malignant diseases. These
protein-based drugs include human natural alpha interferon, monoclonal
antibodies, peptide drugs and therapeutic vaccines. Viragen`s strategy also
includes the development of Avian Transgenic Technology for the large-scale,
cost-effective manufacturing of its portfolio of protein-based drugs, as well
as offering Contract Manufacturing for the entire biopharmaceutical industry.
Viragen is publicly traded on the American Stock Exchange (VRA).
Viragen`s majority owned subsidiary, Viragen International, Inc., is publicly
traded on the Over-The-Counter Bulletin Board (VGNI). Viragen`s key partners
and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer
Center, National Institutes of Health, Cancer Research UK, University of
Nottingham (U.K.), University of Miami, America`s Blood Centers and the German
Red Cross.

For more information, please visit our Web site at: http://www.Viragen.com

Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: [phone]; Fax: [phone]
E-mail: [e-mail]

CJ Pharma Contact:
Jong H. Kim, Director, Global Commercial
Phone: [phone]; Fax: [phone]
E-mail: [e-mail]

The foregoing press release contains forward-looking statements that can
be identified by such terminology such as "expects", "potential", "suggests",
"may", "will", or similar expressions. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause the
actual results to be materially different from any future results, performance
or achievements expressed or implied by such statements. In particular,
management`s expectations regarding future research, development and/or
commercial results could be affected by, among other things, uncertainties
relating to clinical trials and product development; availability of future
financing; unexpected regulatory delays or government regulation generally;
the Company`s ability to obtain or maintain patent and other proprietary
intellectual property protection; and competition in general. Forward-looking
statements speak only as to the date they are made. The Company does not
undertake to update forward-looking statements to reflect circumstances or
events that occur after the date the forward-looking statements are made.



SOURCE Viragen, Inc.
Web Site: http://www.viragen.com
Photo Notes:
http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b AP
Archive: http://photoarchive.ap.org PRN Photo Desk, 888-776-6555
or 212-782-2840
Company News On Call: Company News On-Call:
http://www.prnewswire.com/gh/cnoc/comp/116574.html


--------------------------------------------------------------------------------

Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
More news from PR Newswire...
Copyright © 1996-2002 PR Newswire Association LLC. All Rights Reserved.
A United Business Media company.